We are committed to providing new solutions to the millions of patients suffering from chronic low back pain (CLBP). At any given time, low back pain impacts nearly 30% of the US population, leading to 52 million annual visits to hospitals, emergency departments, outpatient clinics, and physician offices.¹ While the majority of patients with low back pain improve, up to 15% of these patients experience chronic low back pain.²

Today, patients with CLBP are treated with conservative treatments such as physical therapy or injections, medications such as opioids, or potentially surgical options including spinal fusion or total disc replacement. Unfortunately, conservative treatments do not provide adequate relief for the majority of patients and only a small percentage are surgically eligible.

The focus has traditionally been on the intervertebral discs as the primary source of CLBP, known as discogenic pain. Research published over the past 20 years has concluded that vertebral body endplates are a significant source of CLBP. This pain is referred to as vertebrogenic pain and is transmitted via the basivertebral nerve, which is found within the vertebral body.

Based on this research, Relievant developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain.* Intracept, commercially available in the US, is supported by two Level I randomized controlled trials in addition to long-term durability data showing functional and pain improvements are maintained beyond 5 years.

“The Intracept Procedure is a new, minimally invasive option to treat chronic vertebrogenic low back pain. The procedure has been proven to be safe and effective in clinical trials, and is much less invasive than typical surgical options to treat vertebrogenic pain.”

Jeffrey Fischgrund, MD, Chairman, Department of Orthopedics, Beaumont Hospital, Royal Oak and principal investigator of the SMART Trial